Determination of free and total warfarin concentrations in plasma using UPLC MS/MS and its application to a patient samples

Biomedical Chromatography

Volumn 26, Issue 1, 2012, Pages 6-11

  Radwan, Mahasen A ^a   Bawazeer, Ghada A ^a   Aloudah, Nouf M ^a   Alquadeib, Bushra T ^a   Aboul Enein, Hassan Y ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

Etoricoxib; Free warfarin; Ultrafiltrate; UPLC MS MS; Warfarin resistance

Indexed keywords

DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; PATIENT TREATMENT;

CLINICAL MANAGEMENT; DIRECT MEASUREMENT; ETORICOXIB; FREE WARFARIN; INTERNATIONAL NORMALIZED RATIOS; ITS APPLICATIONS; MEASUREMENTS OF; ULTRAFILTRATE; UPLC-MS/MS; WARFARIN RESISTANCE;

MASS SPECTROMETRY;

ACETONITRILE; WARFARIN;

ADULT; ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MASS SPECTROMETRY; PLASMA; REPRODUCIBILITY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ULTRAFILTRATION;

EID: 80255139105     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1616     Document Type: Article

References (30)

1. Albers GW, Dalen JE, Laupacis A, Manning WJ, Petersen P and Singer DE. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119: 194S-206S.
2. Boppana VK, Schaefer WH, Cyronak MJ. High-performance liquid chromatographic determination of warfarin enantiomers in plasma with automated on-line sample enrichment. Journal of Biochemistry and Biophysics Methods 2002; 54: 315-326.
3. Cannegieter SC, Rosendaal FR, Wintzen AR, Van der Meer FJM, Vanderbroucke JP and Briet E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. New Englane Journal of Medicine 1995; 333: 11-17.
4. Costa IM, Soares PJ, Afonso M, Ratado P, Lanao JM and Falcao AC. Therapeutic monitoring of warfarin: the appropriate response marker. Journal of Pharmacy and Pharmacology 2000; 52: 1405-1410.
5. Ezekowitz MD and Falk RH. The increasing need for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Mayo Clinical Proceedings 2004; 79: 904-913.
6. Gage BF, Fihn SD and White RH. Warfarin therapy for an octogenarian who has atrial fibrillation. Annals of Internal Medicine 2001; 134: 465-474.
7. Gibaldi M and Perrier D. Pharmacokinetics, 2nd edn. Marcel Dekker: New York, 1982; 407-417.
8. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clinical Pharmacokinetics 1986; 11: 483-504.
9. Huang C, Yang J, Du Y and Miao L. Measurement of free concentrations of highly protein-bound warfarin in plasma by ultra performance liquid chromatography-tandem mass spectrometry and its correlation with the international normalized ratio. Clinica Chimica Acta 2008; 393: 85-89.
10. Hylek EM. Oral anticoagulants. Pharmacologic issues for use in the elderly. Clinical Geriatric Medicine 2001; 17: 1-13.
11. Kulkarni UP, Swar BD, Karnad DR, Davis S, Patwardhan AM, Kshirsagar NA and Gogtay NJ. A pilot study of the association of pharmacokinetic and pharmacodynamic parameters of warfarin with the dose in patients on long-term anticoagulation. British Journal of Clinical Pharmacology 2008; 65: 787-790.
12. Kwon M-J, Kim H-J, Kim J-W, Lee K-H, Sohn K-H, Cho H-J, On Y-K, Kim J-S and Lee S-Y. Determination of plasma warfarin concentrations in Korean patients and its potential for clinical application. Korean Journal of Laboratory Medicine 2009; 29: 515-523.
13. Levine MN, Raskob G, Landefeld S and Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119(suppl.): S108-S121.
14. Linkins LA, Choi PD and Douketis JD. Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism: a meta-analysis. Annals of Internal Medicine 2003; 139: 893-900.
15. Locatelli I, Kmetec V, Mrhar A and Grabnar I. Determination of warfarin enantiomers and hydroxylated metabolites in human blood plasma by liquid chromatography with achiral and chiral separation. Journal of Chromatography B 2005; 818: 191-198.
16. Majerus PW, Broze GJ and Miletich JP. 1996. Anticoagulant thrombolytic, and antiplatelet drugs. In Hardman JK, Limbird LE (eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn. McGraw-Hill: New York; 1347-1351.
17. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Matrix effect in quantitative LC/MS/MS analyses of biological fluids: a method for determination of finasteride in human plasma at picogram per milliliter concentrations. Analytical Chemistry 1998; 70: 882-889.
18. Merli GJ and Tzanis G. Warfarin: what are the clinical implications of an out-of-range-therapeutic international normalized ratio? Journal of Thrombosis and Thrombolysis 2009; 27: 293-299.
19. Murray B, Coleman R and McWaters D. Pharmacodynamics of warfarin at steady state Theraoeutic Drug Monitoring 1987; 9: 1-5.
20. Naidong W, Ring PR, Midtlien C and Jiang X. Development and validation of a sensitive and robust LC-tandem MS method for the analysis of warfarin enantiomers in human plasma. Journal of Pharm Biomed Anal 2001; 25: 219-226.
21. Osman A, Arbring K and Lindahl TL. A new high-performance liquid chromatographic method for determination of warfarin enantiomers. Journal of Chromatography B 2005; 826: 75-80.
22. Parkash R, Wee V, Gardner MJ, Cox JL, Thompson K, Brownell B and Anderson DR. The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Canadian Journal of Cardiologu 2007; 23: 457-461.
23. Reynolds MW, Fahrbach K, Hauch O, Wygant G, Estok R, Cella C and Nalysynk L. Warfarin anticoagulation and outcomes in patients with atrial fibrillation: a systematic review and meta analysis. Chest 2004; 126: 1938-1945.
24. Ring PR and Bostick JM. Validation of a method for the determination of (R)-warfarin and (S)-warfarin in human plasma using LC with UV detection. Journal of Pharmaceutical and Biomedical Analysis 2000; 22: 573-581.
25. Routledge PA, Shetty HGM, White JP and Collins P. Case studies in therapeutics: warfarin resistance and inefficacy in a man with recurrent thromboembolism, and anticoagulant-associated priapism. British Journal of Clinical Pharmacology 1998; 46: 343-346.
26. Samsa GP and Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. Journal of Thrombosis and Thrombolysis 2000; 9: 283-292.
27. The United States Pharmacopeia Convention. United States Pharmacopoeia XXXIII. Rockville, MD, 2003; 2439.
28. US Food and Drug Administration. Guidance for Industry. Bioanalytical Method Validation, May 2001; (accessed May 2004).
29. Wiedermann CJ and Stockner I. Warfarin-induced bleeding complications: clinical presentation and therapeutic options. Thrombosis Research 2008; 122(suppl. 2): S13-S18.
30. Zuo Z, Wo SK, Lo CMY, Zhou L, Cheng G and You JH. Simultaneous measurement of S-warfarin, R-warfarin, S-7-hydroxywarfarin and R-7-hydroxywarfarin in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis 2010; 52: 305-310.